Escitalopram Oxalate Tablets 10mg

Adult dosage

Safety has not been established for doses exceeding 20mg per day. This drug is administered once daily, in the morning or evening, without regard to meals. Adults Major depressive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. If the dose is to be increased to 20mg, it should be increased at intervals of at least 1 week. In general, 2-4 weeks are required for antidepressant effects to become apparent. Even after symptoms have resolved, at least 6 months of drug treatment is required to ensure a therapeutic response. Panic disorder with or without agoraphobia: It is recommended to administer an initial dose of 5mg per day for 1 week, then increase to 10mg per day. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. The maximum effect appears after approximately 3 months. The safety and efficacy of long-term administration of this drug for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reassess each patient to determine the need for continued treatment. Social anxiety disorder: The usual dose is 10mg once daily. In general, 2-4 weeks are required for symptoms to improve. Thereafter, depending on the patient's response, the dose may be reduced to 5mg per day or increased to a maximum of 20mg per day. Social anxiety disorder is a condition with a chronic course, and continuing treatment for 12 weeks is recommended to ensure a therapeutic response. Long-term treatment in responding patients has been studied for 6 months and should be considered on an individual patient basis to prevent relapse. The usefulness of long-term treatment should be reassessed periodically. Generalized anxiety disorder: The initial dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day after at least 1 week of treatment. A long-term study was conducted in patients who responded to 12 weeks of open-label treatment, with 20mg per day administered for at least 6 months. The physician should periodically reassess the usefulness of long-term treatment with this drug for each patient. Obsessive-compulsive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. A long-term study was conducted in patients who responded to 16 weeks of open-label treatment, with 10mg or 20mg per day administered for at least 24 weeks. Obsessive-compulsive disorder is a chronic condition, and treatment should be continued for a sufficient period to ensure recovery from symptoms. When this drug is administered long term, its usefulness and dosage should be reassessed periodically for each patient. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Caution should be exercised in patients with severe renal impairment (CLCR < 30㎖/min). Patients with hepatic impairment: An initial dose of 5mg per day for the first 2 weeks is recommended. Depending on the patient's response, the dose may be increased to 10mg per day. Discontinuation of treatment: When discontinuing this drug, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. Switching from MAO inhibitors for the treatment of psychiatric disorders: When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this drug, an interval of at least 14 days must be allowed. Conversely, when starting an MAO inhibitor to treat psychiatric disorders, at least 14 days must have elapsed after discontinuing this drug. Other MAO inhibitors, such as linezolid or methylene blue: Patients receiving linezolid or intravenous methylene blue should not start this drug because of the increased risk of serotonin syndrome. For patients who require treatment for a more urgent psychiatric condition, including hospitalization, other interventions should be considered. If urgent administration of linezolid or intravenous methylene blue may be necessary in a patient already receiving this drug, and no alternative to linezolid or intravenous methylene blue is available, and the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome in a particular patient, this drug may be discontinued immediately and linezolid or intravenous methylene blue administered. Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this drug may be restarted 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection) or with intravenous doses of 1mg/kg or less is unclear.

This drug is an antidepressant used in the treatment of psychiatric disorders such as major depression. There may be an increased risk of suicidal thoughts or behavior in children, adolescents, and young adults (ages 18-24), so careful assessment by a physician is required when administering this medication. This medication should not be combined with certain drugs, especially MAO inhibitors, as it may lead to a dangerous side effect called serotonin syndrome, which should never be combined. Additionally, caution is advised for patients with certain heart conditions or those with a prolonged QT interval, as this medication may increase the risk of cardiac arrhythmias. In patients with closed-angle glaucoma or a history of glaucoma, this medication may cause dilatation of the pupils and increase intraocular pressure, so it should be used with caution. While taking this medication, changes in mental symptoms such as anxiety, agitation, aggression, and suicidal impulses should be closely monitored, and family or caregivers should also assist in watching over the patient. During the initial 1-2 weeks of treatment, various side effects such as nausea, insomnia, dizziness, changes in appetite, and decreased libido may occur, but they tend to decrease over time. If the medication is abruptly stopped, withdrawal symptoms such as dizziness, anxiety, and sleep disturbances may occur, so the dosage should be gradually reduced as per the physician's instructions. During pregnancy, the use of this medication may affect the fetus or newborn, so pregnant women must consult a doctor before deciding on its use. In the case of breastfeeding, this medication can be transmitted through breast milk, and considerations should be made for either discontinuing breastfeeding or changing medications. Elderly patients should begin with a lower initial dose and use caution, and attention is also required for patients with impaired liver or kidney function. This medication may require caution when driving or operating machinery; patients should closely observe their condition and consult a specialist if necessary. In case of overdose, symptoms may include central nervous system symptoms, gastrointestinal symptoms, and cardiac abnormalities, requiring immediate access to medical care. This medication should be stored out of reach of children and should not be transferred to other containers.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, loss of appetite, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, nervous hypersensitivity, panic attack, confusion state, aggression, depersonalization, hallucination, mania, suicidal ideation, suicidal behavior, insomnia, drowsiness, dizziness, perceptual disturbances, tremors, taste disorders, sleep disturbances, syncope, serotonin syndrome, movement disorders, motor dysfunction, convulsions, psychomotor agitation, akathisia, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, prolonged QT interval, polymorphic ventricular tachycardia, orthostatic hypotension, sinusitis, yawning, epistaxis, nausea, diarrhea, constipation, vomiting, thirst, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, purpura, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculatory dysfunction, erectile dysfunction, uterine bleeding, menorrhagia, galactorrhea, postpartum hemorrhage, fatigue, fever, edema, headache, xerostomia, abdominal pain, dyspepsia, enteritis, sensory disturbances, cough, asthma, shortness of breath, fracture, palpitations, hypertension, paralysis, extrapyramidal disorder, migraine, chest pain, urinary frequency, tremor, dry mouth, sedation, heartburn, anxiety, visual hallucinations, sexual dysfunction, emotional instability, hypersensitivity, visual impairment, tremors, confusion, diarrhea

This medication should be stored in a tightly closed container that is light-resistant and kept at room temperature between 1 and 30 degrees Celsius. This storage will help maintain the efficacy of the drug.

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle